Journal
PEDIATRIC BLOOD & CANCER
Volume 59, Issue 5, Pages 934-938Publisher
WILEY-BLACKWELL
DOI: 10.1002/pbc.24103
Keywords
Kasabach-Merritt; kaposiform hemangioendothlioma; propranolol; treatment; tufted angioma; vascular tumor
Categories
Funding
- National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS/NIH) [K23AR060274]
Ask authors/readers for more resources
Propranolol is a non-selective beta-adrenergic antagonist successfully used in a case of kaposiform hemangioendothelioma (KHE) associated with KasabachMerritt phenomenon (KMP). We report 11 patients treated with propranolol for KHE and the related variant tufted angioma (TA), six of whom also had KMP. The varied responses to treatment, with only 36% responding in our series, demonstrate the need for further study of this medication before routine use for these indications. Pediatr Blood Cancer 2012; 59: 934938. (C) 2012 Wiley Periodicals, Inc.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available